Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.

Dainippon Sumitomo Pharma (DSP) has prevailed in a legal case brought against it by a smaller Japanese company regarding a terminated licensing deal for a quinolone antibacterial.

Wakunaga Pharmaceutical has taken its fight with fellow Japanese company Dainippon Sumitomo Pharma (DSP) to the Supreme Court. The small firm has appealed a recent Osaka High Court decision that rejected its claims against DSP in a long-running dispute over a terminated 1998 licensing deal for a quinolone antibacterial. DSP brought the High Court appeal following a 2007 district court decision ordering it to pay ¥890 million ($8.9 million) in damages to Wakunaga (scripnews.com, March 27th, 2009). Wakunaga first filed suit in 2004, claiming then that Dainippon (which merged with Sumitomo Pharma in 2005) had acted improperly.